|
1
|
Kaltsas GA, Nomikos P, Kontogeorgos G,
Buchfelder M and Grossman AB: Clinical review: Diagnosis and
management of pituitary carcinomas. J Clin Endocrinol Metab.
90:3089–3099. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fernandez A, Karavitaki N and Wass JA:
Prevalence of pituitary adenomas: A community-based,
cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol
(Oxf). 72:377–382. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dai C, Feng M, Liu X, Ma S, Sun B, Bao X,
Yao Y, Deng K, Wang Y, Xing B, et al: Refractory pituitary adenoma:
A novel classification for pituitary tumors. Oncotarget.
7:83657–83668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raverot G, Burman P, McCormack A, Heaney
A, Petersenn S, Popovic V, Trouillas J and Dekkers OM; European
Society of Endocrinology, : European society of endocrinology
clinical practice guidelines for the management of aggressive
pituitary tumours and carcinomas. Eur J Endocrinol. 178:G1–G24.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heaney A: Management of aggressive
pituitary adenomas and pituitary carcinomas. J Neurooncol.
117:459–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lasolle H, Cortet C, Castinetti F, Cloix
L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C,
Sadoul JL, et al: Temozolomide treatment can improve overall
survival in aggressive pituitary tumors and pituitary carcinomas.
Eur J Endocrinol. 176:769–777. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Losa M, Bogazzi F, Cannavo S, Ceccato F,
Curtò L, De Marinis L, Iacovazzo D, Lombardi G, Mantovani G, Mazza
E, et al: Temozolomide therapy in patients with aggressive
pituitary adenomas or carcinomas. J Neurooncol. 126:519–525. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
9
|
Treiber T, Treiber N and Meister G:
Regulation of microRNA biogenesis and its crosstalk with other
cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berindan-Neagoe I, Monroig Pdel C,
Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer
diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feng Y, Mao ZG, Wang X, Du Q, Jian M, Zhu
D, Xiao Z, Wang HJ and Zhu YH: MicroRNAs and target genes in
pituitary adenomas. Horm Metab Res. 50:179–192. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Ieva A, Butz H, Niamah M, Rotondo F, De
Rosa S, Sav A, Yousef GM, Kovacs K and Cusimano MD: MicroRNAs as
biomarkers in pituitary tumors. Neurosurgery. 75:181–189;
discussion 188–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang QJ and Xu C: The role of microRNAs
in the pathogenesis of pituitary tumors. Front Biosci (Landmark
Ed). 21:1–7. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei Z, Zhou C, Liu M, Yao Y, Sun J, Xiao
J, Ma W, Zhu H and Wang R: MicroRNA involvement in a metastatic
non-functioning pituitary carcinoma. Pituitary. 18:710–721. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roche M, Wierinckx A, Croze S, Rey C,
Legras-Lachuer C, Morel AP, Fusco A, Raverot G, Trouillas J and
Lachuer J: Deregulation of miR-183 and KIAA0101 in aggressive and
malignant pituitary tumors. Front Med (Lausanne).
2:542015.PubMed/NCBI
|
|
18
|
Edgar R, Domrachev M and Lash AE: Gene
expression omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res 41 (Database Issue).
D991–D995. 2013.
|
|
20
|
Chou CH, Shrestha S, Yang CD, Chang NW,
Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase
update 2018: A resource for experimentally validated
microRNA-target interactions. Nucleic Acids Res 46D. D296–D302.
2018. View Article : Google Scholar
|
|
21
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kanehisa M, Furumichi M, Tanabe M, Sato Y
and Morishima K: KEGG: New perspectives on genomes, pathways,
diseases and drugs. Nucleic Acids Res 45D. D353–D361. 2017.
View Article : Google Scholar
|
|
23
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
von Mering C, Huynen M, Jaeggi D, Schmidt
S, Bork P and Snel B: STRING: A database of predicted functional
associations between proteins. Nucleic Acids Res. 31:258–261. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bandettini WP, Kellman P, Mancini C,
Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and
Arai AE: MultiContrast delayed enhancement (MCODE) improves
detection of subendocardial myocardial infarction by late
gadolinium enhancement cardiovascular magnetic resonance: A
clinical validation study. J Cardiovasc Magn Reson. 14:832012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maere S, Heymans K and Kuiper M: BiNGO: A
cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dworakowska D and Grossman AB: The
pathophysiology of pituitary adenomas. Best Pract Res Clin
Endocrinol Metab. 23:525–541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak
A, Ren SG, Bruyette D and Melmed S: EGFR as a therapeutic target
for human, canine, and mouse ACTH-secreting pituitary adenomas. J
Clin Invest. 121:4712–4721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fukuoka H, Cooper O, Mizutani J, Tong Y,
Ren SG, Bannykh S and Melmed S: HER2/ErbB2 receptor signaling in
rat and human prolactinoma cells: Strategy for targeted
prolactinoma therapy. Mol Endocrinol. 25:92–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vlotides G, Siegel E, Donangelo I, Gutman
S, Ren SG and Melmed S: Rat prolactinoma cell growth regulation by
epidermal growth factor receptor ligands. Cancer Res. 68:6377–6386.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cooper O, Mamelak A, Bannykh S, Carmichael
J, Bonert V, Lim S, Cook-Wiens G and Ben-Shlomo A: Prolactinoma
ErbB receptor expression and targeted therapy for aggressive
tumors. Endocrine. 46:318–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Donovan LE, Arnal AV, Wang SH and Odia Y:
Widely metastatic atypical pituitary adenoma with mTOR pathway
STK11(F298L) mutation treated with everolimus therapy. CNS Oncol.
5:203–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ortiz LD, Syro LV, Scheithauer BW, Ersen
A, Uribe H, Fadul CE, Rotondo F, Horvath E and Kovacs K: Anti-VEGF
therapy in pituitary carcinoma. Pituitary. 15:445–449. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
D'Angelo D, Palmieri D, Mussnich P, Roche
M, Wierinckx A, Raverot G, Fedele M, Croce CM, Trouillas J and
Fusco A: Altered microRNA expression profile in human pituitary GH
adenomas: Down-regulation of miRNA targeting HMGA1, HMGA2, and
E2F1. J Clin Endocrinol Metab. 97:E1128–E1138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mussnich P, Raverot G, Jaffrain-Rea ML,
Fraggetta F, Wierinckx A, Trouillas J, Fusco A and D'Angelo D:
Downregulation of miR-410 targeting the cyclin B1 gene plays a role
in pituitary gonadotroph tumors. Cell Cycle. 14:2590–2597. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Finotello F and Di Camillo B: Measuring
differential gene expression with RNA-seq: Challenges and
strategies for data analysis. Brief Funct Genomics. 14:130–142.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Farhan M, Wang H, Gaur U, Little PJ, Xu J
and Zheng W: FOXO signaling pathways as therapeutic targets in
cancer. Int J Biol Sci. 13:815–827. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu F, Zhang J, Hu G, Liu L and Liang W:
Hypoxia and TGF-β1 induced PLOD2 expression improve the migration
and invasion of cervical cancer cells by promoting
epithelial-to-mesenchymal transition (EMT) and focal adhesion
formation. Cancer Cell Int. 17:542017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Matano F, Yoshida D, Ishii Y, Tahara S,
Teramoto A and Morita A: Endocan, a new invasion and angiogenesis
marker of pituitary adenomas. J Neurooncol. 117:485–491. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cooper O, Vlotides G, Fukuoka H, Greene MI
and Melmed S: Expression and function of ErbB receptors and ligands
in the pituitary. Endocr Relat Cancer. 18:R197–R211. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin Y, Liu J, Huang Y, Liu D, Zhang G and
Kan H: microRNA-489 plays an anti-metastatic role in human
hepatocellular carcinoma by targeting matrix metalloproteinase-7.
Transl Oncol. 10:211–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang B, Ji S, Ma F, Ma Q, Lu X and Chen
X: miR-489 acts as a tumor suppressor in human gastric cancer by
targeting PROX1. Am J Cancer Res. 6:2021–2030. 2016.PubMed/NCBI
|
|
44
|
Chai P, Tian J, Zhao D, Zhang H, Cui J,
Ding K and Liu B: GSE1 negative regulation by miR-489-5p promotes
breast cancer cell proliferation and invasion. Biochem Biophys Res
Commun. 471:123–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu D, Liu R, Meng L, Zhang Y, Lu G and Ma
P: Long non-coding RNA ENST01108 promotes carcinogenesis of glioma
by acting as a molecular sponge to modulate miR-489. Biomed
Pharmacother. 100:20–28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kikkawa N, Hanazawa T, Fujimura L, Nohata
N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki
N: miR-489 is a tumour-suppressive miRNA target PTPN11 in
hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer.
103:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li J, Qu W, Jiang Y, Sun Y, Cheng Y, Zou T
and Du S: miR-489 suppresses proliferation and invasion of human
bladder cancer cells. Oncol Res. 24:391–398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao S, Liu H, Hou S, Wu L, Yang Z, Shen J,
Zhou L, Zheng SS and Jiang B: miR-489 suppresses tumor growth and
invasion by targeting HDAC7 in colorectal cancer. Clin Transl
Oncol. 20:703–712. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xiao J, Li G, Zhou J, Wang S, Liu D, Shu
G, Zhou J and Ren F: MicroRNA-520b functions as a tumor suppressor
in colorectal cancer by inhibiting defective in cullin neddylation
1 domain containing 1 (DCUN1D1). Oncol Res. 26:593–604. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu X, Wang F, Tian L, Wang T, Zhang W, Li
B and Bai YA: MicroRNA-520b affects the proliferation of human
glioblastoma cells by directly targeting cyclin D1. Tumour Biol.
37:7921–7928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang W, Kong G, Zhang J, Wang T, Ye L and
Zhang X: MicroRNA-520b inhibits growth of hepatoma cells by
targeting MEKK2 and cyclin D1. PLoS One. 7:e314502012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lu YC, Cheng AJ, Lee LY, You GR, Li YL,
Chen HY and Chang JT: miR-520b as a novel molecular target for
suppressing stemness phenotype of head-neck cancer by inhibiting
CD44. Sci Rep. 7:20422017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue
L, Bai X, Zhang Z, Zhang W, Zhang X and Ye L: miR-520b regulates
migration of breast cancer cells by targeting hepatitis B
X-interacting protein and interleukin-8. J Biol Chem.
286:13714–13722. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jin K, Zhao W, Xie X, Pan Y, Wang K and
Zhang H: miR-520b restrains cell growth by targeting HDAC4 in lung
cancer. Thorac Cancer. 9:1249–1254. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li S, Zhang H, Ning T, Wang X, Liu R, Yang
H, Han Y, Deng T, Zhou L, Zhang L, et al: miR-520b/e regulates
proliferation and migration by simultaneously targeting EGFR in
gastric cancer. Cell Physiol Biochem. 40:1303–1315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liang S, Chen L, Huang H and Zhi D: The
experimental study of miRNA in pituitary adenomas. Turk Neurosurg.
23:721–727. 2013.PubMed/NCBI
|
